The estimated Net Worth of James L Ltullis Growth Fund... is at least $4.59 Milhão dollars as of 15 June 2023. James Fund owns over 167 units of Exagen Inc stock worth over $4,592,992 and over the last few years James sold XGN stock worth over $0.
James has made over 1 trades of the Exagen Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently James bought 167 units of XGN stock worth $519 on 15 June 2023.
The largest trade James's ever made was buying 167 units of Exagen Inc stock on 15 June 2023 worth over $519. On average, James trades about 167 units every 0 days since 2023. As of 15 June 2023 James still owns at least 1,515,839 units of Exagen Inc stock.
You can see the complete history of James Fund stock trades at the bottom of the page.
Over the last 5 years, insiders at Exagen Inc have traded over $8,628,989 worth of Exagen Inc stock and bought 556,568 units worth $6,283,309 . The most active insiders traders include James L L Tullis, Bio Exagen, L.P.H.I.G. Gpii..., eJeffrey Thomas Elliott. On average, Exagen Inc executives and independent directors trade stock every 48 days with the average trade being worth of $109,189. The most recent stock trade was executed by John Aballi on 16 May 2024, trading 40,401 units of XGN stock currently worth $77,570.
exagen diagnostics, inc. is a patient focused, discovery driven, clia-certified, cap-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of rheumatology and autoimmune diseases. committed to personalized medicine, our avise tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. for more information on our company, please visit www.exagen.com. for more information on avise testing services, please visit www.avisetest.com.
Exagen Inc executives and other stock owners filed with the SEC include: